Saturday 17 October 2026
Export PBM’s income statement to Excel — free account
Psyence Biomedical Ltd.
In the quarter to September 2025, EPS was flat and free cash flow fell 707.2%, each against the same quarter a year earlier.
4.22
0.10
−2.31%
Follow PBM
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 231,562.50 | 231,328.13 | 192,187.50 | 471.88 | 25.86 | 1.92 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | 234,375.00 | 247,265.63 | 341,015.63 | 295,359.38 | 709.38 | 32.42 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 10 | 12 | 12 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | 8 | 8 | (51) | (51) | 1 | (7) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | 0 | — | — | — | 8 | 8 | 0 | (51) | 1 | (7) | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | 0.25 | 0.25 | (6.14) | (29,211.54) | 32.75 | (12.56) | |||||
| Cash flow | — | — | — | — | (0.03) | (0.02) | 0.00 | (1,732.59) | (120.85) | (14.74) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | (3.35) | (0.32) | 0.00 | |||||
| Free cash flow | — | — | — | — | (0.03) | (0.02) | 0.00 | (1,735.94) | (121.17) | (14.74) | |||||
| Book value | — | — | — | — | 7.24 | 7.49 | (1.32) | (6,454.41) | 217.54 | 30.68 | |||||
| Shares, m | — | — | — | — | 33 | 33 | 8 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (1) | (1) | — | (3) | (4) | (8) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | (1) | (1) | — | (3) | (4) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | (13) | (11) | (11) | 6 | 8 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | (1) | 0 | (1) | (1) | (6) | (7) | |||||
| Shareholders’ equity | — | — | — | — | 237 | 245 | (11) | (11) | 7 | 17 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | 6.42 | 3.11 | (39.34) | (4,518.56) | 23.95 | (55.75) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (415.57) | (41.24) | |||||
| ROE | — | — | — | — | 0.00 | 3.33 | (54.66) | 149.52 | (47.61) | (58.62) | |||||
Negative figures in brackets.
Charts ten years each
Psyence Biomedical Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANEB Anebulo Pharmaceuticals, Inc. | $17.6M | — (loss-making) | — | — | n/m | +6.58% (above 0%: growing) | — | 0.00% | Compare |
| ACGN Aceragen, Inc. | $17.1M | — (loss-making) | — (loss-making) | +2,394.95% (above 0%: growing) | n/m | −115.67% (below 0%: shrinking) | 100.00% | (834.33%) | Compare |
| RADX Radiopharm Theranostics Limited - Sponsored ADR | $17.0M | — | — | — | — | −137.75% (below 0%: shrinking) | — | — | Compare |
| DYAI Dyadic International Inc. | $16.8M | — (loss-making) | — (loss-making) | −0.57% (below 0%: shrinking) | n/m | −1,298.54% (below 0%: shrinking) | (2.39%) | (213.73%) | Compare |
| PBM Psyence Biomedical Ltd. | $16.5M | 0.2× | — | — | n/m | −707.20% (below 0%: shrinking) | — | 0.00% | |
| TCRX TScan Therapeutics, Inc. | $16.2M | — (loss-making) | — (loss-making) | −65.83% (below 0%: shrinking) | n/m | +18.95% (above 0%: growing) | 100.00% | (2,901.33%) | Compare |
| AKTX Akari Therapeutics PLC | $15.5M | — (loss-making) | — | — | n/m | +4.51% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $15.3M | — (loss-making) | — (loss-making) | +2.75% (above 0%: growing) | n/m | −97.84% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $16.5M | — | — | −0.57% | — | −46.66% | 50.00% | 0.00% |
Psyence Biomedical Ltd. (PBM) key facts
- Psyence Biomedical Ltd. (PBM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PBM traded at $4.22, a market capitalization of $16.5 million.
- Return on equity was −58.6% and debt-to-equity 0.00.